Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cerebrolysin vs Zilucoplan (Zilbrysq)
An educational, source-based comparison of Cerebrolysin and Zilucoplan (Zilbrysq) — how each peptide works, what it's researched for, and what to know before going deeper.
Porcine-derived peptide mixture researched in neurologic recovery.
A mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue. Research suggests neurotrophic-like activity mimicking BDNF, NGF, and GDNF signaling.
- Ischemic stroke recovery
- Traumatic brain injury
- Vascular dementia and Alzheimer's adjunct
- • Approved in many countries; not FDA-approved in the US.
- • Mixture composition is not fully characterized.
Macrocyclic peptide complement C5 inhibitor for generalized myasthenia gravis.
A synthetic 15-amino-acid macrocyclic peptide that binds complement component C5 and blocks its cleavage to C5a/C5b, preventing formation of the membrane attack complex at the neuromuscular junction. Self-administered subcutaneously.
- Generalized myasthenia gravis (anti-AChR antibody positive)
- • FDA-approved 2023.
- • Requires meningococcal vaccination — risk of serious meningococcal infection.
- • Injection-site reactions common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cerebrolysin | Cerebrolysin in acute ischemic stroke (CARS trial) | Stroke | 2016 | Improved early motor recovery in combination with rehabilitation. |
| Zilucoplan (Zilbrysq) | RAISE phase 3 trial of zilucoplan in gMG | Lancet Neurology | 2023 | Significant improvement in MG-ADL and QMG scores vs placebo at week 12. |
Side-effect & safety grid
- Approved in many countries; not FDA-approved in the US.
- Mixture composition is not fully characterized.
- FDA-approved 2023.
- Requires meningococcal vaccination — risk of serious meningococcal infection.
- Injection-site reactions common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cerebrolysin vs Zilucoplan (Zilbrysq) — Key differences
- Class: Cerebrolysin is classified as Neurotrophic · Mixture, while Zilucoplan (Zilbrysq) is Complement Inhibitor · Neuromuscular.
- Primary research focus: Cerebrolysin — ischemic stroke recovery; Zilucoplan (Zilbrysq) — generalized myasthenia gravis (anti-achr antibody positive).
- Tag: Cognition · Neuroprotection vs FDA-Approved · Neuromuscular.